SB-525 Gene Therapy Phase 1/2 Trial Begins for Hemophilia A Patients – Hemophilia News Today
Hemophilia News Today |
SB-525 Gene Therapy Phase 1/2 Trial Begins for Hemophilia A Patients
Hemophilia News Today The first patient in a Phase 1/2 clinical trial (“the Alta trial”) designed to assess safety and tolerability of SB-525 gene therapy has received treatment. Sangamo Therapeutics, in a collaboration with Pfizer, is developing the SB-525 gene therapy to … |
